Craig Porter
Concepts (316)
Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Burns | 32 | 2024 | 163 | 9.100 |
Why?
| | Muscle, Skeletal | 32 | 2023 | 804 | 4.400 |
Why?
| | Adipose Tissue, Brown | 15 | 2025 | 44 | 4.010 |
Why?
| | Energy Metabolism | 17 | 2025 | 302 | 3.590 |
Why?
| | Mitochondria, Muscle | 9 | 2018 | 40 | 3.520 |
Why?
| | Mitochondria | 16 | 2025 | 430 | 3.030 |
Why?
| | Thermogenesis | 9 | 2025 | 29 | 2.800 |
Why?
| | Adipose Tissue, White | 9 | 2022 | 35 | 2.560 |
Why?
| | Muscle Proteins | 13 | 2021 | 321 | 1.350 |
Why?
| | Glucose | 3 | 2023 | 355 | 1.200 |
Why?
| | Housing, Animal | 2 | 2025 | 18 | 1.160 |
Why?
| | Temperature | 2 | 2025 | 183 | 1.070 |
Why?
| | Exercise Therapy | 6 | 2021 | 100 | 1.020 |
Why?
| | Cachexia | 4 | 2019 | 27 | 0.990 |
Why?
| | Resistance Training | 7 | 2021 | 101 | 0.930 |
Why?
| | Oxygen Consumption | 6 | 2018 | 198 | 0.900 |
Why?
| | Muscle Fibers, Skeletal | 3 | 2019 | 63 | 0.890 |
Why?
| | Physical Conditioning, Animal | 2 | 2023 | 59 | 0.870 |
Why?
| | Proteomics | 2 | 2023 | 329 | 0.830 |
Why?
| | Insulin Resistance | 6 | 2025 | 275 | 0.830 |
Why?
| | Adipocytes | 2 | 2021 | 132 | 0.800 |
Why?
| | Animals | 23 | 2025 | 13505 | 0.790 |
Why?
| | Male | 45 | 2025 | 26761 | 0.780 |
Why?
| | Lipid Metabolism | 5 | 2019 | 187 | 0.770 |
Why?
| | Peripheral Arterial Disease | 1 | 2023 | 75 | 0.760 |
Why?
| | Muscular Atrophy | 3 | 2021 | 71 | 0.730 |
Why?
| | Carnitine | 3 | 2019 | 68 | 0.710 |
Why?
| | Humans | 61 | 2025 | 52483 | 0.700 |
Why?
| | Mice, Inbred BALB C | 6 | 2020 | 312 | 0.680 |
Why?
| | Cell Respiration | 6 | 2019 | 41 | 0.680 |
Why?
| | Quadriceps Muscle | 4 | 2021 | 47 | 0.670 |
Why?
| | Oxidative Phosphorylation | 3 | 2025 | 46 | 0.640 |
Why?
| | Diabetes Mellitus | 1 | 2023 | 316 | 0.620 |
Why?
| | Sepsis | 2 | 2019 | 239 | 0.610 |
Why?
| | Mitochondrial Proteins | 6 | 2017 | 89 | 0.610 |
Why?
| | Mitochondria, Liver | 2 | 2018 | 69 | 0.600 |
Why?
| | Musculoskeletal Diseases | 1 | 2018 | 51 | 0.590 |
Why?
| | Stress, Physiological | 2 | 2016 | 183 | 0.590 |
Why?
| | Methylhydrazines | 1 | 2017 | 1 | 0.560 |
Why?
| | Down-Regulation | 2 | 2017 | 346 | 0.560 |
Why?
| | Mitochondrial Diseases | 2 | 2015 | 45 | 0.550 |
Why?
| | Mice | 12 | 2025 | 5949 | 0.550 |
Why?
| | Sex Characteristics | 1 | 2018 | 198 | 0.530 |
Why?
| | Adipose Tissue | 3 | 2025 | 204 | 0.530 |
Why?
| | Amino Acids | 3 | 2020 | 377 | 0.530 |
Why?
| | Oxidative Stress | 3 | 2018 | 807 | 0.520 |
Why?
| | Electron Transport Complex II | 1 | 2015 | 7 | 0.480 |
Why?
| | Electron Transport Complex I | 1 | 2015 | 21 | 0.480 |
Why?
| | Mice, Inbred C57BL | 5 | 2025 | 1884 | 0.480 |
Why?
| | Ion Channels | 4 | 2015 | 70 | 0.440 |
Why?
| | Female | 29 | 2025 | 28171 | 0.430 |
Why?
| | Liver | 6 | 2023 | 1156 | 0.420 |
Why?
| | Muscle Strength | 7 | 2021 | 130 | 0.410 |
Why?
| | Quality of Life | 1 | 2018 | 879 | 0.400 |
Why?
| | Young Adult | 11 | 2021 | 4329 | 0.380 |
Why?
| | Health Status | 1 | 2013 | 294 | 0.360 |
Why?
| | Fungal Proteins | 3 | 2020 | 117 | 0.360 |
Why?
| | Recovery of Function | 3 | 2021 | 199 | 0.360 |
Why?
| | Aging | 2 | 2017 | 701 | 0.360 |
Why?
| | Adult | 15 | 2025 | 14161 | 0.360 |
Why?
| | Diet, High-Fat | 4 | 2021 | 236 | 0.350 |
Why?
| | Blood Glucose | 4 | 2017 | 473 | 0.330 |
Why?
| | Fibroblast Growth Factors | 2 | 2021 | 46 | 0.330 |
Why?
| | Metabolic Diseases | 2 | 2025 | 46 | 0.320 |
Why?
| | Muscular Diseases | 2 | 2020 | 63 | 0.320 |
Why?
| | Inflammation | 3 | 2024 | 641 | 0.320 |
Why?
| | Citrate (si)-Synthase | 3 | 2019 | 11 | 0.310 |
Why?
| | Obesity | 5 | 2025 | 1162 | 0.310 |
Why?
| | RNA, Messenger | 3 | 2017 | 1132 | 0.300 |
Why?
| | Cold Temperature | 4 | 2017 | 53 | 0.300 |
Why?
| | Basal Metabolism | 3 | 2018 | 33 | 0.290 |
Why?
| | Child | 15 | 2022 | 7248 | 0.290 |
Why?
| | Subcutaneous Fat | 2 | 2019 | 19 | 0.290 |
Why?
| | Case-Control Studies | 5 | 2017 | 1201 | 0.260 |
Why?
| | Child, Preschool | 7 | 2018 | 4076 | 0.260 |
Why?
| | Pregnancy in Diabetics | 2 | 2024 | 27 | 0.250 |
Why?
| | Adolescent | 10 | 2018 | 6739 | 0.240 |
Why?
| | Lipids | 2 | 2023 | 155 | 0.230 |
Why?
| | Rats | 2 | 2023 | 3220 | 0.230 |
Why?
| | Exercise | 5 | 2021 | 547 | 0.230 |
Why?
| | Hypertrophy, Left Ventricular | 1 | 2024 | 42 | 0.230 |
Why?
| | Receptors, Purinergic | 1 | 2024 | 12 | 0.220 |
Why?
| | Beverages | 2 | 2021 | 57 | 0.220 |
Why?
| | Body Composition | 5 | 2021 | 338 | 0.220 |
Why?
| | Limb Salvage | 1 | 2023 | 40 | 0.210 |
Why?
| | Protein Biosynthesis | 3 | 2021 | 258 | 0.200 |
Why?
| | Weight Loss | 1 | 2025 | 248 | 0.200 |
Why?
| | Regeneration | 2 | 2020 | 79 | 0.200 |
Why?
| | Signal Transduction | 4 | 2024 | 1671 | 0.200 |
Why?
| | Ischemia | 1 | 2023 | 150 | 0.190 |
Why?
| | Cardiomyopathy, Hypertrophic | 1 | 2022 | 33 | 0.190 |
Why?
| | Trauma Severity Indices | 2 | 2019 | 51 | 0.190 |
Why?
| | Time Factors | 4 | 2017 | 2968 | 0.190 |
Why?
| | Blood Platelets | 1 | 2024 | 259 | 0.190 |
Why?
| | Proteolysis | 2 | 2019 | 101 | 0.190 |
Why?
| | Diabetes, Gestational | 1 | 2022 | 53 | 0.180 |
Why?
| | Gene Transfer Techniques | 1 | 2021 | 40 | 0.180 |
Why?
| | Body Mass Index | 4 | 2018 | 689 | 0.180 |
Why?
| | Renal Insufficiency, Chronic | 1 | 2024 | 187 | 0.180 |
Why?
| | Catecholamines | 1 | 2021 | 44 | 0.180 |
Why?
| | Bed Rest | 1 | 2021 | 36 | 0.180 |
Why?
| | Oxandrolone | 2 | 2018 | 10 | 0.180 |
Why?
| | Overnutrition | 1 | 2020 | 11 | 0.170 |
Why?
| | Apoptosis | 2 | 2016 | 1119 | 0.170 |
Why?
| | Middle Aged | 9 | 2025 | 13028 | 0.170 |
Why?
| | Propranolol | 2 | 2018 | 78 | 0.170 |
Why?
| | Adiposity | 3 | 2019 | 143 | 0.170 |
Why?
| | Hepatocytes | 2 | 2019 | 190 | 0.170 |
Why?
| | Phenylalanine | 1 | 2020 | 132 | 0.170 |
Why?
| | Myofibrils | 2 | 2020 | 20 | 0.170 |
Why?
| | Milk Proteins | 1 | 2020 | 77 | 0.160 |
Why?
| | Prospective Studies | 4 | 2018 | 2481 | 0.160 |
Why?
| | Capillaries | 1 | 2019 | 50 | 0.160 |
Why?
| | Leukocytes, Mononuclear | 1 | 2019 | 123 | 0.160 |
Why?
| | Gonads | 1 | 2019 | 6 | 0.160 |
Why?
| | Metformin | 2 | 2017 | 76 | 0.160 |
Why?
| | Receptors, Aryl Hydrocarbon | 1 | 2019 | 28 | 0.160 |
Why?
| | GTPase-Activating Proteins | 1 | 2019 | 25 | 0.150 |
Why?
| | Adrenergic beta-Antagonists | 2 | 2021 | 110 | 0.150 |
Why?
| | Adaptation, Physiological | 1 | 2019 | 110 | 0.150 |
Why?
| | Up-Regulation | 2 | 2017 | 454 | 0.150 |
Why?
| | Infant, Newborn | 3 | 2024 | 2867 | 0.150 |
Why?
| | Sarcopenia | 1 | 2019 | 98 | 0.150 |
Why?
| | Electron Transport | 1 | 2018 | 26 | 0.150 |
Why?
| | Hep G2 Cells | 1 | 2018 | 39 | 0.150 |
Why?
| | Weight Gain | 1 | 2019 | 240 | 0.150 |
Why?
| | Superoxides | 1 | 2018 | 46 | 0.140 |
Why?
| | Immunologic Memory | 1 | 2017 | 31 | 0.140 |
Why?
| | National Institute of General Medical Sciences (U.S.) | 1 | 2017 | 1 | 0.140 |
Why?
| | Cystathionine beta-Synthase | 1 | 2017 | 17 | 0.140 |
Why?
| | Adenomatous Polyps | 1 | 2017 | 8 | 0.140 |
Why?
| | T-Lymphocyte Subsets | 1 | 2017 | 41 | 0.140 |
Why?
| | Blotting, Western | 2 | 2016 | 590 | 0.140 |
Why?
| | Chagas Disease | 1 | 2017 | 3 | 0.140 |
Why?
| | Appetite Regulation | 1 | 2017 | 12 | 0.140 |
Why?
| | Triglycerides | 1 | 2018 | 165 | 0.140 |
Why?
| | Neuropeptides | 1 | 2017 | 37 | 0.140 |
Why?
| | Burns, Electric | 1 | 2017 | 2 | 0.140 |
Why?
| | Myocardium | 2 | 2017 | 453 | 0.140 |
Why?
| | Multiple Organ Failure | 1 | 2017 | 49 | 0.140 |
Why?
| | Glycogen | 1 | 2017 | 44 | 0.140 |
Why?
| | Adipocytes, Brown | 1 | 2017 | 9 | 0.140 |
Why?
| | Membrane Potential, Mitochondrial | 1 | 2017 | 39 | 0.140 |
Why?
| | Rats, Zucker | 1 | 2017 | 73 | 0.140 |
Why?
| | Research Support as Topic | 1 | 2017 | 44 | 0.140 |
Why?
| | Physical Endurance | 1 | 2017 | 34 | 0.140 |
Why?
| | NF-E2-Related Factor 2 | 1 | 2017 | 47 | 0.140 |
Why?
| | Fatty Acids | 1 | 2017 | 149 | 0.140 |
Why?
| | Colon | 1 | 2017 | 104 | 0.130 |
Why?
| | Rats, Wistar | 1 | 2017 | 193 | 0.130 |
Why?
| | Infant | 4 | 2022 | 3733 | 0.130 |
Why?
| | Aged | 7 | 2021 | 10121 | 0.130 |
Why?
| | Chronic Disease | 2 | 2017 | 586 | 0.130 |
Why?
| | Palmitoylcarnitine | 1 | 2016 | 7 | 0.130 |
Why?
| | Blood Cells | 1 | 2016 | 45 | 0.130 |
Why?
| | Mice, Knockout | 4 | 2021 | 879 | 0.130 |
Why?
| | Gastrointestinal Tract | 1 | 2017 | 108 | 0.130 |
Why?
| | Intestinal Mucosa | 1 | 2017 | 224 | 0.130 |
Why?
| | Ventricular Dysfunction, Left | 1 | 2017 | 108 | 0.130 |
Why?
| | Satellite Cells, Skeletal Muscle | 1 | 2016 | 25 | 0.130 |
Why?
| | Cardiomyopathies | 1 | 2017 | 121 | 0.130 |
Why?
| | Motor Activity | 1 | 2017 | 223 | 0.130 |
Why?
| | Trauma Centers | 1 | 2017 | 209 | 0.130 |
Why?
| | Neck | 1 | 2016 | 97 | 0.120 |
Why?
| | Electron Transport Chain Complex Proteins | 1 | 2015 | 10 | 0.120 |
Why?
| | Physical Education and Training | 1 | 2015 | 23 | 0.120 |
Why?
| | Proton Ionophores | 1 | 2015 | 3 | 0.120 |
Why?
| | Uncoupling Agents | 1 | 2015 | 5 | 0.120 |
Why?
| | Carbonyl Cyanide m-Chlorophenyl Hydrazone | 1 | 2015 | 5 | 0.120 |
Why?
| | Oligomycins | 1 | 2015 | 8 | 0.120 |
Why?
| | Reactive Oxygen Species | 1 | 2017 | 421 | 0.120 |
Why?
| | Severity of Illness Index | 2 | 2018 | 1026 | 0.120 |
Why?
| | DNA, Mitochondrial | 1 | 2015 | 114 | 0.110 |
Why?
| | Acute Disease | 1 | 2015 | 373 | 0.110 |
Why?
| | Cardiovascular System | 1 | 2015 | 53 | 0.110 |
Why?
| | Androgens | 1 | 2014 | 70 | 0.110 |
Why?
| | Insulin | 4 | 2019 | 479 | 0.110 |
Why?
| | Anabolic Agents | 1 | 2014 | 44 | 0.110 |
Why?
| | Lung | 2 | 2015 | 509 | 0.110 |
Why?
| | Treatment Outcome | 2 | 2023 | 5422 | 0.110 |
Why?
| | Rats, Sprague-Dawley | 1 | 2018 | 1563 | 0.110 |
Why?
| | Risk Factors | 1 | 2023 | 3889 | 0.110 |
Why?
| | Biomedical Research | 1 | 2017 | 256 | 0.110 |
Why?
| | Overweight | 1 | 2016 | 224 | 0.110 |
Why?
| | Rest | 1 | 2014 | 60 | 0.110 |
Why?
| | Cohort Studies | 2 | 2015 | 1542 | 0.110 |
Why?
| | Infusions, Intravenous | 1 | 2013 | 220 | 0.100 |
Why?
| | Hypoglycemic Agents | 1 | 2014 | 211 | 0.100 |
Why?
| | Pregnancy | 3 | 2025 | 2680 | 0.100 |
Why?
| | Biopsy | 1 | 2014 | 605 | 0.100 |
Why?
| | Fluorodeoxyglucose F18 | 3 | 2017 | 188 | 0.090 |
Why?
| | Double-Blind Method | 2 | 2020 | 713 | 0.080 |
Why?
| | Professional Practice | 1 | 2008 | 18 | 0.070 |
Why?
| | Dietary Proteins | 2 | 2021 | 252 | 0.070 |
Why?
| | Body Weight | 2 | 2021 | 523 | 0.070 |
Why?
| | Aged, 80 and over | 1 | 2015 | 3392 | 0.070 |
Why?
| | Torque | 2 | 2018 | 16 | 0.070 |
Why?
| | Mice, Transgenic | 2 | 2019 | 552 | 0.070 |
Why?
| | Renal Dialysis | 1 | 2008 | 179 | 0.070 |
Why?
| | Mitochondria, Heart | 2 | 2017 | 37 | 0.060 |
Why?
| | Gene Expression | 2 | 2020 | 618 | 0.060 |
Why?
| | Homeostasis | 2 | 2019 | 201 | 0.060 |
Why?
| | Kinetics | 2 | 2018 | 626 | 0.060 |
Why?
| | Body Surface Area | 2 | 2016 | 27 | 0.060 |
Why?
| | Retrospective Studies | 3 | 2024 | 6607 | 0.060 |
Why?
| | Nutritional Support | 2 | 2015 | 35 | 0.060 |
Why?
| | Exercise Test | 2 | 2017 | 141 | 0.060 |
Why?
| | Oxidation-Reduction | 2 | 2016 | 326 | 0.060 |
Why?
| | Radiopharmaceuticals | 2 | 2017 | 204 | 0.060 |
Why?
| | Diabetes Mellitus, Type 2 | 2 | 2025 | 560 | 0.060 |
Why?
| | Pediatrics | 1 | 2008 | 293 | 0.060 |
Why?
| | Gene Expression Regulation | 2 | 2020 | 990 | 0.060 |
Why?
| | Purinergic Antagonists | 1 | 2024 | 7 | 0.060 |
Why?
| | Phenotype | 2 | 2019 | 789 | 0.060 |
Why?
| | Bariatric Surgery | 1 | 2025 | 43 | 0.060 |
Why?
| | Acute Kidney Injury | 1 | 2008 | 319 | 0.060 |
Why?
| | Positron-Emission Tomography | 2 | 2017 | 301 | 0.050 |
Why?
| | Hemostasis | 1 | 2024 | 60 | 0.050 |
Why?
| | Disease Models, Animal | 2 | 2017 | 1478 | 0.050 |
Why?
| | Thrombosis | 1 | 2024 | 253 | 0.040 |
Why?
| | Respiration | 1 | 2021 | 101 | 0.040 |
Why?
| | Polyphenols | 1 | 2021 | 38 | 0.040 |
Why?
| | Muscle Contraction | 1 | 2021 | 117 | 0.040 |
Why?
| | Immobilization | 1 | 2020 | 15 | 0.040 |
Why?
| | Leucine | 1 | 2021 | 114 | 0.040 |
Why?
| | Forearm | 1 | 2020 | 32 | 0.040 |
Why?
| | Tomography, X-Ray Computed | 2 | 2017 | 1165 | 0.040 |
Why?
| | Nutritional Physiological Phenomena | 1 | 2019 | 22 | 0.040 |
Why?
| | Body Temperature Regulation | 1 | 2019 | 30 | 0.040 |
Why?
| | NF-kappa B | 1 | 2021 | 322 | 0.040 |
Why?
| | Hypertrophy | 1 | 2019 | 52 | 0.040 |
Why?
| | Mothers | 1 | 2022 | 270 | 0.040 |
Why?
| | Rabbits | 1 | 2019 | 375 | 0.040 |
Why?
| | Drinking | 1 | 2019 | 43 | 0.040 |
Why?
| | Ubiquitin-Protein Ligases | 1 | 2019 | 96 | 0.040 |
Why?
| | Tamoxifen | 1 | 2019 | 60 | 0.040 |
Why?
| | Athletic Injuries | 1 | 2020 | 192 | 0.040 |
Why?
| | HEK293 Cells | 1 | 2019 | 229 | 0.040 |
Why?
| | Autophagy | 1 | 2019 | 193 | 0.040 |
Why?
| | Acetyl-CoA Carboxylase | 1 | 2017 | 13 | 0.040 |
Why?
| | Artifacts | 1 | 2018 | 55 | 0.040 |
Why?
| | Adoptive Transfer | 1 | 2017 | 29 | 0.040 |
Why?
| | Host-Parasite Interactions | 1 | 2017 | 17 | 0.040 |
Why?
| | Hydrogen Sulfide | 1 | 2017 | 6 | 0.040 |
Why?
| | HCT116 Cells | 1 | 2017 | 30 | 0.040 |
Why?
| | Exercise Tolerance | 1 | 2017 | 46 | 0.040 |
Why?
| | Antioxidant Response Elements | 1 | 2017 | 3 | 0.040 |
Why?
| | Gastric Inhibitory Polypeptide | 1 | 2017 | 2 | 0.040 |
Why?
| | Glucagon | 1 | 2017 | 24 | 0.030 |
Why?
| | Transplantation, Heterologous | 1 | 2017 | 79 | 0.030 |
Why?
| | Transcription, Genetic | 1 | 2019 | 378 | 0.030 |
Why?
| | Ghrelin | 1 | 2017 | 29 | 0.030 |
Why?
| | History, 21st Century | 1 | 2017 | 59 | 0.030 |
Why?
| | Malaria | 1 | 2017 | 42 | 0.030 |
Why?
| | Lymphocyte Activation | 1 | 2017 | 172 | 0.030 |
Why?
| | History, 20th Century | 1 | 2017 | 96 | 0.030 |
Why?
| | Feeding Behavior | 1 | 2019 | 192 | 0.030 |
Why?
| | Protein Binding | 1 | 2019 | 667 | 0.030 |
Why?
| | Superoxide Dismutase | 1 | 2017 | 119 | 0.030 |
Why?
| | Mice, Nude | 1 | 2017 | 265 | 0.030 |
Why?
| | Child, Hospitalized | 1 | 2017 | 31 | 0.030 |
Why?
| | Drug Administration Schedule | 1 | 2017 | 374 | 0.030 |
Why?
| | Promoter Regions, Genetic | 1 | 2019 | 467 | 0.030 |
Why?
| | ATP-Dependent Proteases | 1 | 2016 | 1 | 0.030 |
Why?
| | Endopeptidase Clp | 1 | 2016 | 2 | 0.030 |
Why?
| | PAX7 Transcription Factor | 1 | 2016 | 10 | 0.030 |
Why?
| | HeLa Cells | 1 | 2017 | 265 | 0.030 |
Why?
| | MyoD Protein | 1 | 2016 | 8 | 0.030 |
Why?
| | Palmitates | 1 | 2016 | 29 | 0.030 |
Why?
| | Mitochondrial Membrane Transport Proteins | 1 | 2016 | 18 | 0.030 |
Why?
| | Metabolism | 1 | 2016 | 25 | 0.030 |
Why?
| | Myosin Heavy Chains | 1 | 2016 | 25 | 0.030 |
Why?
| | Hyperinsulinism | 1 | 2016 | 30 | 0.030 |
Why?
| | Heart Rate | 1 | 2018 | 318 | 0.030 |
Why?
| | Cell Movement | 1 | 2017 | 268 | 0.030 |
Why?
| | CD4-Positive T-Lymphocytes | 1 | 2017 | 164 | 0.030 |
Why?
| | Multiprotein Complexes | 1 | 2016 | 25 | 0.030 |
Why?
| | Caspase 3 | 1 | 2016 | 95 | 0.030 |
Why?
| | Metabolomics | 1 | 2017 | 150 | 0.030 |
Why?
| | Lipoproteins | 1 | 2016 | 42 | 0.030 |
Why?
| | Leptin | 1 | 2017 | 148 | 0.030 |
Why?
| | TOR Serine-Threonine Kinases | 1 | 2016 | 80 | 0.030 |
Why?
| | Microscopy, Electron | 1 | 2016 | 75 | 0.030 |
Why?
| | Peroxidase | 1 | 2015 | 17 | 0.030 |
Why?
| | Fluorescent Antibody Technique | 1 | 2016 | 111 | 0.030 |
Why?
| | Neutrophil Infiltration | 1 | 2015 | 24 | 0.030 |
Why?
| | Cell Survival | 1 | 2017 | 612 | 0.030 |
Why?
| | Sex Factors | 1 | 2018 | 727 | 0.030 |
Why?
| | Real-Time Polymerase Chain Reaction | 1 | 2016 | 185 | 0.030 |
Why?
| | Lipid Peroxidation | 1 | 2015 | 97 | 0.030 |
Why?
| | Proteasome Endopeptidase Complex | 1 | 2016 | 117 | 0.030 |
Why?
| | Linear Models | 1 | 2016 | 287 | 0.030 |
Why?
| | Antioxidants | 1 | 2017 | 256 | 0.030 |
Why?
| | Cells, Cultured | 1 | 2019 | 1567 | 0.030 |
Why?
| | Muscle Strength Dynamometer | 1 | 2014 | 12 | 0.030 |
Why?
| | Cell Line | 1 | 2017 | 1030 | 0.030 |
Why?
| | Glucose Clamp Technique | 1 | 2014 | 15 | 0.030 |
Why?
| | Multivariate Analysis | 1 | 2016 | 591 | 0.030 |
Why?
| | Collagen | 1 | 2016 | 211 | 0.030 |
Why?
| | Survivors | 1 | 2015 | 120 | 0.030 |
Why?
| | Calorimetry, Indirect | 1 | 2014 | 26 | 0.030 |
Why?
| | Human Growth Hormone | 1 | 2014 | 50 | 0.030 |
Why?
| | Testosterone | 1 | 2014 | 141 | 0.030 |
Why?
| | Organ Size | 1 | 2014 | 228 | 0.030 |
Why?
| | Absorptiometry, Photon | 1 | 2014 | 162 | 0.030 |
Why?
| | DNA Damage | 1 | 2015 | 305 | 0.030 |
Why?
| | Gene Expression Regulation, Neoplastic | 1 | 2017 | 857 | 0.030 |
Why?
| | Recombinant Proteins | 1 | 2014 | 483 | 0.030 |
Why?
| | Immunohistochemistry | 1 | 2016 | 979 | 0.030 |
Why?
| | Cytokines | 1 | 2016 | 623 | 0.030 |
Why?
| | Macrophages | 1 | 2015 | 379 | 0.030 |
Why?
| | Ambulatory Care | 1 | 2014 | 239 | 0.020 |
Why?
| | Gene Expression Profiling | 1 | 2017 | 1105 | 0.020 |
Why?
| | Predictive Value of Tests | 1 | 2015 | 944 | 0.020 |
Why?
| | Follow-Up Studies | 1 | 2015 | 2279 | 0.020 |
Why?
| | United States | 1 | 2017 | 5192 | 0.020 |
Why?
|
|
Porter's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically based on a person's publications. Keywords from attributed publications are matched to keywords from the MeSH. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|